Fortress Biotech Balance Sheet Health
Financial Health criteria checks 3/6
Fortress Biotech has a total shareholder equity of $37.4M and total debt of $53.8M, which brings its debt-to-equity ratio to 143.9%. Its total assets and total liabilities are $159.9M and $122.5M respectively.
Key information
143.85%
Debt to equity ratio
US$53.78m
Debt
| Interest coverage ratio | n/a |
| Cash | US$74.39m |
| Equity | US$37.38m |
| Total liabilities | US$122.51m |
| Total assets | US$159.90m |
Recent financial health updates
Recent updates
Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
Aug 17
FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Mar 11Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Oct 29Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Jul 26There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Dec 29There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Aug 18Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients
Aug 11David Jin is the new finance chief of Fortress Biotech
Jul 22Financial Position Analysis
Short Term Liabilities: FBIO's short term assets ($110.4M) exceed its short term liabilities ($57.5M).
Long Term Liabilities: FBIO's short term assets ($110.4M) exceed its long term liabilities ($65.0M).
Debt to Equity History and Analysis
Debt Level: FBIO has more cash than its total debt.
Reducing Debt: FBIO's debt to equity ratio has increased from 78.1% to 143.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FBIO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: FBIO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 2.6% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/27 18:51 |
| End of Day Share Price | 2025/08/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fortress Biotech, Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |